OA11034A - Polypeptides comprenant des domaines de la protéine gax impliqués dans la repression de transcription et/ou interagissant avec d'aoutres protéines acides nucleiques correspondants et leurs utilisations - Google Patents

Polypeptides comprenant des domaines de la protéine gax impliqués dans la repression de transcription et/ou interagissant avec d'aoutres protéines acides nucleiques correspondants et leurs utilisations Download PDF

Info

Publication number
OA11034A
OA11034A OA9900083A OA9900083A OA11034A OA 11034 A OA11034 A OA 11034A OA 9900083 A OA9900083 A OA 9900083A OA 9900083 A OA9900083 A OA 9900083A OA 11034 A OA11034 A OA 11034A
Authority
OA
OAPI
Prior art keywords
gax
protein
polypeptide
dna
fragment
Prior art date
Application number
OA9900083A
Other languages
English (en)
French (fr)
Inventor
Abderrahim Mahfoudi
Alain Fournier
Christophe Marcireau
Didier Branellec
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of OA11034A publication Critical patent/OA11034A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/797—Lipid particle
    • Y10S977/798—Lipid particle having internalized material
    • Y10S977/799—Containing biological material
    • Y10S977/80—Nucleic acid, e.g. DNA or RNA
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
OA9900083A 1996-10-18 1999-04-16 Polypeptides comprenant des domaines de la protéine gax impliqués dans la repression de transcription et/ou interagissant avec d'aoutres protéines acides nucleiques correspondants et leurs utilisations OA11034A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9612730A FR2754822B1 (fr) 1996-10-18 1996-10-18 Polypeptides comprenant des domaines de la proteine gax, impliques dans la repression de transcription et/ou interagissant avec d'autres proteines, acides nucleiques correspondants et leurs utilisations

Publications (1)

Publication Number Publication Date
OA11034A true OA11034A (fr) 2003-03-06

Family

ID=9496803

Family Applications (1)

Application Number Title Priority Date Filing Date
OA9900083A OA11034A (fr) 1996-10-18 1999-04-16 Polypeptides comprenant des domaines de la protéine gax impliqués dans la repression de transcription et/ou interagissant avec d'aoutres protéines acides nucleiques correspondants et leurs utilisations

Country Status (22)

Country Link
US (1) US6121005A (no)
EP (1) EP0941243A1 (no)
JP (1) JP2001503615A (no)
KR (1) KR20000049249A (no)
CN (1) CN1237980A (no)
AP (1) AP9901510A0 (no)
AU (1) AU741586B2 (no)
BG (1) BG63548B1 (no)
BR (1) BR9711947A (no)
CA (1) CA2268045A1 (no)
CZ (1) CZ131899A3 (no)
EA (1) EA003694B1 (no)
FR (1) FR2754822B1 (no)
HU (1) HUP9903956A3 (no)
IL (1) IL129478A0 (no)
NO (1) NO991830L (no)
NZ (1) NZ335283A (no)
OA (1) OA11034A (no)
PL (1) PL332874A1 (no)
SK (1) SK51199A3 (no)
WO (1) WO1998017686A1 (no)
ZA (1) ZA979390B (no)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001289652A1 (en) * 2000-06-28 2002-01-08 Aventis Pharma S.A. Compositions and methods for regulating the cell cycle using a ki gene or polypeptide
US8124598B2 (en) 2006-09-14 2012-02-28 Sharon Sageman 7-keto DHEA for psychiatric use
US20100160274A1 (en) * 2007-09-07 2010-06-24 Sharon Sageman 7-KETO DHEA for Psychiatric Use
JP2013522169A (ja) * 2010-02-24 2013-06-13 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 炎症および好中球減少症の処置のための化合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856121A (en) * 1994-02-24 1999-01-05 Case Western Reserve University Growth arrest homebox gene
US5554181A (en) * 1994-05-04 1996-09-10 Regents Of The University Of Minnesota Stent
GB9422175D0 (en) * 1994-11-03 1994-12-21 Univ Dundee Indentification of the p21 waf1-pcna interaction site and therapeutic applications thereof
FR2732357B1 (fr) * 1995-03-31 1997-04-30 Rhone Poulenc Rorer Sa Vecteurs viraux et utilisation pour le traitement des desordres hyperproliferatifs, notamment de la restenose
FR2740344B1 (fr) * 1995-10-31 1997-11-21 Rhone Poulenc Rorer Sa Application de la proteine gax au traitement de cancers

Also Published As

Publication number Publication date
BG103342A (en) 2000-05-31
FR2754822B1 (fr) 1998-11-27
EP0941243A1 (fr) 1999-09-15
EA199900387A1 (ru) 1999-10-28
JP2001503615A (ja) 2001-03-21
NO991830D0 (no) 1999-04-16
FR2754822A1 (fr) 1998-04-24
KR20000049249A (ko) 2000-07-25
US6121005A (en) 2000-09-19
AP9901510A0 (en) 1999-06-30
BR9711947A (pt) 1999-08-24
CA2268045A1 (fr) 1998-04-30
HUP9903956A3 (en) 2002-01-28
AU4871397A (en) 1998-05-15
SK51199A3 (en) 2000-04-10
PL332874A1 (en) 1999-10-25
HUP9903956A2 (hu) 2000-03-28
IL129478A0 (en) 2000-02-29
CZ131899A3 (cs) 1999-07-14
CN1237980A (zh) 1999-12-08
AU741586B2 (en) 2001-12-06
NZ335283A (en) 2001-02-23
EA003694B1 (ru) 2003-08-28
NO991830L (no) 1999-06-16
BG63548B1 (bg) 2002-04-30
ZA979390B (en) 1998-05-12
WO1998017686A1 (fr) 1998-04-30

Similar Documents

Publication Publication Date Title
FR2732357A1 (fr) Vecteurs viraux et utilisation pour le traitement des desordres hyperproliferatifs, notamment de la restenose
JP2007312778A (ja) ＨＭＧ蛋白質（ｈｉｇｈｍｏｂｉｌｉｔｙｇｒｏｕｐｐｒｏｔｅｉｎ）遺伝子の核酸配列およびそれらの使用
KR20220044811A (ko) Crispr/cas13을 사용하는 표적화된 트랜스-이어맞추기
US10456480B2 (en) Treating glaucoma, cardiovascular diseases, and renal diseases
KR20080036015A (ko) 글루코오스 유도성 인슐린 발현 및 당뇨병 치료 방법
EP0839194B1 (fr) Variants de la proteine p53 et utilisations therapeutiques
US6300484B1 (en) DNA encoding DP. 75 and a process for its use
KR20100109912A (ko) 핵산을 세포로 전달하기 위한 약학 조성물 및 방법
CA2214451A1 (fr) Systeme d'expression conditionnel
OA11034A (fr) Polypeptides comprenant des domaines de la protéine gax impliqués dans la repression de transcription et/ou interagissant avec d'aoutres protéines acides nucleiques correspondants et leurs utilisations
FR2740454A1 (fr) Peptides capables d'inhiber l'endocytose de l'app et sequences nucleotidiques correspondantes
CA2250099A1 (fr) Sequences en amont du gene sm22, vecteurs les contenant et leurs utilisations therapeutiques, notamment dans le traitement des maladies vasculaires
EP0941319A1 (fr) Peptides capables d'inhiber l'endocytose de l'app et sequences nucleotidiques correspondantes
WO1996038556A2 (fr) Deltap62, ses variants, sequences d'acides nucleiques les codant, et leurs utilisations en therapie genique anti-cancereuse
CN116322742A (zh) 用于治疗同种异体移植物血管病、烟雾病、烟雾病综合征和内膜增殖的组合物和方法
MXPA99003470A (en) Polypeptides comprising gax protein domains, involved in repressing transcription and/or interacting with other proteins, corresponding nucleic acids and their use
CA2343922A1 (fr) Utilisation de promoteurs specifiques hybrides pour controler l'expression tissulaire
CA2353304A1 (fr) Polypeptides capables d'interagir avec la topoisomerase iii alpha humaine
FR2805266A1 (fr) Compositions utilisables pour reguler l'activite de la parkine
FR2783839A1 (fr) Utilisation de promoteurs specifiques hybrides pour controler l'expression tissulaire
TW201139675A (en) NeuroD1 gene expression in non-endocrine pancreatic epithelial cells (NEPECs)